医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Morinaga Milk Expands Lactoferrin Production Capacity in German Subsidiary “MILEI GmbH”

2020年10月28日 PM02:52
このエントリーをはてなブックマークに追加


 

TOKYO

Morinaga Milk Industry Co., Ltd. (TOKYO: 2264) (hereafter, “Morinaga Milk”) hereby announces that its subsidiary MILEI GmbH (hereafter, “MILEI”), which has the largest share* of the global market in terms of production volume of the functional ingredient lactoferrin, will increase more than double its production capacity with the aim to enhance its lactoferrin production.

* According to data for 2019 released by Absolute Reports

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006307/en/

Powdered lactoferrin (Photo: Morinaga Milk)

Powdered lactoferrin (Photo: Morinaga Milk)

1. Overview

(1) Location: Kemptener Strasse 91, 88299 Leutkirch, Germany
(2) Product manufactured: Lactoferrin
(3) Total investment: EUR 15,000,000 (approx. JPY 1.8 billion*) * Assuming an exchange rate of 120 yen to one euro
(4) Production capacity: Approx. 170 tons (more than double that of fiscal 2019)
(5) Launch of operations: April 2021 (planned)

2. Background and purpose

As a functional ingredient for infant formula, supplements and other foods, the demand for lactoferrin has been growing particularly in Western countries and Asia.

Considering the increasing attention towards health and nutrition, the demand for lactoferrin as a functional ingredient with health value is expected to grow over the long term globally.

Morinaga Milk Group considers lactoferrin as an important functional ingredient to support people’s health and nutrition worldwide and has been conducting fundamental research and seeking commercial applications for over six decades.

Morinaga Milk Group is aiming to increase the sales of its own lactoferrin-related products with expanding production capacity in MILEI, and will flexibly respond to the long-term increasing demand of lactoferrin.

Having the largest production share of lactoferrin, Morinaga Milk Group will increase the production of MILEI and contribute to the well-being of people.

3. Effect on financial results

The investment will not affect financial results for the fiscal year ending March 31, 2021.

[Reference information]

MILEI GmbH

MILEI is based in the southern German city of Leutkirch, where its production facilities are located.

Founded in 1972, MILEI has a history of almost five decades since its start of production in 1975. MILEI offers lactoferrin, whey protein concentrate, lactose and other dairy ingredients mainly in Europe and Asia. Many companies, including global food manufacturers, use MILEI’s ingredients for infant formula, sports nutrition and others. Under the global strategy of Morinaga Milk, MILEI plays an important role supporting production and sales of ingredients for infant formula, supplements and others.

Lactoferrin

Present in most exocrine secretions such as breast milk and saliva of humans and other mammals, lactoferrin is a component with a wide range of physiological functions. The high amount of lactoferrin found in human breast milk, especially in colostrum, is considered to offer important and protective benefits to newborns.

Discovered by Danish scientists in 1939, lactoferrin as a remarkable functional ingredient, has been intensively researched by scientists worldwide, as shown by the increasing number of the studies in the graph (Figure 1). Paying high attention to the fact that lactoferrin is highly abundant in colostrum, Morinaga Milk has been focusing its research efforts on lactoferrin over the long term to develop infant formula that closely resembles breast milk. Since its initial publication of a research paper on lactoferrin in 1963, Morinaga Milk has been reporting its benefits through academic forums, conferences and publications.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201027006307/en/

CONTACT

International Division, Morinaga Milk Industry Co., Ltd.

Yoshihiko Ushida

Tamami Shibata

TEL: +81-3-3798-0152

E-mail: interntl@morinagamilk.co.jp

https://www.morinagamilk.co.jp/english/

https://www.milei.de (MILEI GmbH Website)

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • PierianDx宣布与Illumina扩大伙伴关系,在全球市场支持癌症基因组报告
  • PierianDxが世界市場でのがんゲノムレポート作成を支えるべくイルミナとの提携拡大を発表
  • Market Access Transformation (MAT)取得Silversmith Capital Partners领投的第一笔机构融资
  • New Frontier Health Corporation Announces Third Quarter 2020 Financial Results
  • TAITRA Launches Online Medical Show